-
NF-κB p65–Mediated YAP Inactivation Drives Pyroptosis in UC
2026-05-22
This study elucidates how NF-κB p65 activation in ulcerative colitis promotes phosphorylation and inactivation of YAP, relieving repression of NLRP3 and exacerbating colonic epithelial pyroptosis. The findings offer mechanistic insight into the cross-talk between NF-κB signaling and Hippo pathway regulation during intestinal inflammation, highlighting potential therapeutic targets for inflammation research.
-
AI-Driven Discovery of Senolytics: Machine Learning Advances
2026-05-21
The referenced study pioneers a machine learning approach to identify new senolytic compounds using only published data, significantly reducing drug screening costs. This method validates ginkgetin, periplocin, and oleandrin as potent senolytics, offering a scalable pathway for early-stage drug discovery in cancer and age-related disease research.
-
20-HETE–TRPV1–MrgprA3+ Axis Drives Itch Sensitization in Der
2026-05-21
This study elucidates how the lipid metabolite 20-HETE activates TRPV1 channels on MrgprA3+ sensory neurons, converting pain signals into itch in chronic dermatitis. The findings provide a mechanistic rationale for targeting this pathway to alleviate chronic itch, with implications for translational research in somatosensory disorders.
-
Oxaliplatin: Applied Workflows and Resistance Solutions in C
2026-05-20
Oxaliplatin, a platinum-based chemotherapeutic agent, is central to preclinical cancer models and advanced chemotherapy resistance research. This article details best-practice workflows, actionable troubleshooting, and the latest mechanistic insights—empowering translational breakthroughs for apoptosis induction and DNA damage modeling.
-
EV-Transferred ACLY Drives TAM Differentiation in HCC Progre
2026-05-20
This study demonstrates that hepatocellular carcinoma (HCC) cells secrete extracellular vesicles (EVs) containing ATP-citrate lyase (ACLY), which are preferentially taken up by monocytes and reprogram them toward immunosuppressive tumor-associated macrophages (TAMs). The findings reveal a distinct metabolic mechanism fueling HCC progression and highlight the therapeutic potential of targeting EV-transferred ACLY to enhance immunotherapy efficacy.
-
EPZ-6438: Optimizing EZH2 Inhibitor Workflows for Cancer Res
2026-05-19
EPZ-6438 stands out as a highly selective EZH2 inhibitor, streamlining epigenetic cancer research with nanomolar potency and robust assay compatibility. This guide delivers actionable workflow enhancements, troubleshooting strategies, and expert insights for maximizing EPZ-6438 performance in both in vitro and in vivo models.
-
Technical Guidance for Angiotensin I/II (1-5) in RAS Researc
2026-05-19
Angiotensin I/II (1-5) provides a defined Asp-Arg-Val-Tyr-Ile peptide fragment for modeling blood pressure regulation and aldosterone signaling within renin-angiotensin system (RAS) workflows. It is suited to cardiovascular and renal studies, but should not be used for unrelated peptide or exploratory signaling research due to its specific mechanism and solubility characteristics.
-
Rotavirus Drives Nrf2 Downregulation and Redox Defense Colla
2026-05-18
This study demonstrates that progressive rotavirus infection leads to a marked downregulation of the redox-sensitive transcription factor Nrf2 and its downstream cytoprotective targets, independent of canonical redox or proteasomal control pathways. These insights highlight new complexities in host–virus interactions and provide a mechanistic foundation for further redox signaling research.
-
Leupeptin Hemisulfate Salt: Precision Tools for Translationa
2026-05-18
Explore how Leupeptin hemisulfate salt enables next-generation studies of protease activity regulation, protein degradation, and viral replication inhibition. Integrating mechanistic insight with strategic guidance, this thought-leadership article demonstrates how APExBIO’s Leupeptin empowers translational researchers to bridge fundamental biochemistry and clinical innovation.
-
Otilonium Bromide in Translational Research: Precision for C
2026-05-17
Explore the mechanistic depth and translational potential of Otilonium Bromide, a high-purity antimuscarinic agent. This thought-leadership article bridges biological rationale, experimental design, and strategic guidance, empowering researchers to leverage Otilonium Bromide for advanced neuroscience and smooth muscle studies.
-
Anti-Diabetic Drugs and Fracture Risk: Insights from Network
2026-05-16
This systematic review and network meta-analysis rigorously evaluated the association between various anti-diabetic drugs and fracture risk in type 2 diabetes mellitus (T2DM) patients. While most agents, including SGLT2 inhibitors such as Ertugliflozin (PF-04971729), showed no significant effect on fracture risk, some drugs increased or decreased risk, highlighting the need for individualized therapeutic decisions.
-
Strategic Cell Tracking in Inflammatory Disease: DiD (DiDC 1
2026-05-15
This thought-leadership article explores how DiD (DiDC 18 (5)) enables reliable plasma membrane labeling and cell tracking in translational models of inflammatory disease. Bridging mechanistic insight from recent advances in diabetic periodontitis with experimental and strategic guidance, it demonstrates how DiD's unique properties facilitate high-fidelity, immunofluorescence-compatible workflows even in challenging, high-autofluorescence tissue environments. The piece contextualizes APExBIO's DiD probe within the competitive landscape, offers actionable protocol parameters, and charts a forward-looking outlook for translational researchers.
-
RSL3 Drives PARP1-Mediated Apoptosis Pathways in Ferroptosis
2026-05-15
This study reveals that the ferroptosis inducer RSL3 promotes apoptosis through two distinct mechanisms involving PARP1: caspase-dependent cleavage and suppression of full-length PARP1 via m6A modification. These findings advance understanding of cell death crosstalk and suggest RSL3's therapeutic value in overcoming PARP inhibitor resistance.
-
Stiripentol as an LDH Inhibitor: Protocols for Advanced Rese
2026-05-14
Stiripentol, a noncompetitive LDH inhibitor, unlocks precise control of lactate metabolism for studies in epilepsy and tumor immunometabolism. This article delivers actionable workflows, troubleshooting tips, and direct connections to the latest reference findings—positioning Stiripentol from APExBIO as an indispensable tool for translational metabolic research.
-
Lysosomal β-Galactosidase Staining Kit: Optimizing Senescenc
2026-05-14
The Lysosomal β-Galactosidase Staining Kit empowers researchers to distinctly visualize lysosomal enzyme activity, ensuring robust control stains in cellular senescence assays. Its polystyrene compatibility and artifact-minimizing chemistry elevate reproducibility—even in high-throughput oncology workflows.